PURPOSE: To compare the ability of the ultrasmall superparamagnetic iron oxide (USPIO) SHU555C vs. gadopentetate dimeglumine (Gd-DTPA) to detect antigen-induced monoarthritis with MRI. MATERIALS AND METHODS: Twelve seven-week-old female rats with an antigen-induced monoarthritis of the right knee were randomly assigned to two groups. Animals in group I (N = 6) underwent MRI using T1-weighted gradient-echo sequences before injection and at 2, 9, 17, 25, 33, 40, 47, 55, and 63 minutes postinjection (p.i.) of Gd-DTPA on day 1, and before injection and at 3, 23, 43, and 123 minutes p.i. of SHU555C on day 2. Animals in group II (N = 6) were imaged before injection and at 3, 23, 43, and 123 minutes p.i. using identical sequences. Signal-to-noise ratios (SNRs) and relative enhancement (DeltaSI%) of arthritic and normal synovium were determined from region-of-interest (ROI) measurements in consensus reading by two experienced radiologists. Data were tested for significant differences between the two agents and between the arthritic and normal knees using a mixed-effect model and F-tests (P < 0.05). Joints were processed for histopathology as the gold standard. RESULTS: USPIO and Gd-DTPA showed significant enhancement differences (P < 0.001). USPIO provided a progressive and persistent enhancement of arthritic joints while Gd-DTPA provided an early and rapidly declining enhancement. Maximal enhancement in synovitis was 400% at 40-120 minutes p.i. of USPIO vs. 300% at two minutes p.i. of Gd-DTPA. USPIO provided a significant higher difference in enhancement between the arthritic and normal synovium than Gd-DTPA (P < 0.001). Histopathology confirmed marked inflammatory synovial changes in all arthritis-induced right knee joints and normal synovium in all left knee joints. CONCLUSION: Both USPIO and Gd-DTPA detect arthritis by positive T1-enhancement. Compared to standard Gd-DTPA, the USPIO SHU555C provides a comparable maximal T1-enhancement (at two minutes p.i for Gd-DTPA and between 43 and 123 minutes p.i. for SHU555C), but in addition it provides a prolonged T1-enhancement of synovitis and a higher difference between the relative enhancement of arthritic and normal synovium. Copyright 2006 Wiley-Liss, Inc.
PURPOSE: To compare the ability of the ultrasmall superparamagnetic iron oxide (USPIO) SHU555C vs. gadopentetate dimeglumine (Gd-DTPA) to detect antigen-induced monoarthritis with MRI. MATERIALS AND METHODS: Twelve seven-week-old female rats with an antigen-induced monoarthritis of the right knee were randomly assigned to two groups. Animals in group I (N = 6) underwent MRI using T1-weighted gradient-echo sequences before injection and at 2, 9, 17, 25, 33, 40, 47, 55, and 63 minutes postinjection (p.i.) of Gd-DTPA on day 1, and before injection and at 3, 23, 43, and 123 minutes p.i. of SHU555C on day 2. Animals in group II (N = 6) were imaged before injection and at 3, 23, 43, and 123 minutes p.i. using identical sequences. Signal-to-noise ratios (SNRs) and relative enhancement (DeltaSI%) of arthritic and normal synovium were determined from region-of-interest (ROI) measurements in consensus reading by two experienced radiologists. Data were tested for significant differences between the two agents and between the arthritic and normal knees using a mixed-effect model and F-tests (P < 0.05). Joints were processed for histopathology as the gold standard. RESULTS: USPIO and Gd-DTPA showed significant enhancement differences (P < 0.001). USPIO provided a progressive and persistent enhancement of arthritic joints while Gd-DTPA provided an early and rapidly declining enhancement. Maximal enhancement in synovitis was 400% at 40-120 minutes p.i. of USPIO vs. 300% at two minutes p.i. of Gd-DTPA. USPIO provided a significant higher difference in enhancement between the arthritic and normal synovium than Gd-DTPA (P < 0.001). Histopathology confirmed marked inflammatory synovial changes in all arthritis-induced right knee joints and normal synovium in all left knee joints. CONCLUSION: Both USPIO and Gd-DTPA detect arthritis by positive T1-enhancement. Compared to standard Gd-DTPA, the USPIO SHU555C provides a comparable maximal T1-enhancement (at two minutes p.i for Gd-DTPA and between 43 and 123 minutes p.i. for SHU555C), but in addition it provides a prolonged T1-enhancement of synovitis and a higher difference between the relative enhancement of arthritic and normal synovium. Copyright 2006 Wiley-Liss, Inc.
Authors: C S Reiner; A M Lutz; F Tschirch; J M Froehlich; S Gaillard; B Marincek; D Weishaupt Journal: Eur Radiol Date: 2009-03-28 Impact factor: 5.315
Authors: C Kaneko; N Nitta; K Tsuchiya; S Watanabe; A Nitta-Seko; S Ohta; H Otani; A Sonoda; K Murata; M Shiomi Journal: Br J Radiol Date: 2015-06-17 Impact factor: 3.039
Authors: Ashok J Theruvath; Ali Rashidi; Ramya R Nyalakonda; Raffi S Avedian; Robert J Steffner; Sheri L Spunt; Heike E Daldrup-Link Journal: Pediatr Radiol Date: 2021-08-19
Authors: J-C Brisset; V Desestret; S Marcellino; E Devillard; F Chauveau; F Lagarde; S Nataf; N Nighoghossian; Y Berthezene; M Wiart Journal: Eur Radiol Date: 2009-08-25 Impact factor: 5.315
Authors: Maryam Aghighi; Ashok J Theruvath; Anuj Pareek; Laura L Pisani; Raphael Alford; Anne M Muehe; Tarsheen K Sethi; Samantha J Holdsworth; Florette K Hazard; Dita Gratzinger; Sandra Luna-Fineman; Ranjana Advani; Sheri L Spunt; Heike E Daldrup-Link Journal: Clin Cancer Res Date: 2018-05-15 Impact factor: 12.531
Authors: Cindy Strehl; Timo Gaber; Lionel Maurizi; Martin Hahne; Roman Rauch; Paula Hoff; Thomas Häupl; Margarethe Hofmann-Amtenbrink; A Robin Poole; Heinrich Hofmann; Frank Buttgereit Journal: Int J Nanomedicine Date: 2015-05-08
Authors: Azza Gramoun; Lindsey A Crowe; Lionel Maurizi; Wolfgang Wirth; Frank Tobalem; Kerstin Grosdemange; Geraldine Coullerez; Felix Eckstein; Marije I Koenders; Wim B Van den Berg; Heinrich Hofmann; Jean-Paul Vallée Journal: Arthritis Res Ther Date: 2014-06-23 Impact factor: 5.156
Authors: Heike E Daldrup-Link; Ashok J Theruvath; Ali Rashidi; Michael Iv; Robbie G Majzner; Sheri L Spunt; Stuart Goodman; Michael Moseley Journal: Pediatr Radiol Date: 2021-05-27